Clinical trial
Safety and Effectiveness of h5G1.1-mAb for Dermatomyositis
NCT00005571 · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), NIH · Completed
Key facts
| NCT number | NCT00005571 |
|---|---|
| Title | Safety and Effectiveness of h5G1.1-mAb for Dermatomyositis |
| Official title | A Randomized, Third-Party-Blind, Placebo-Controlled Pilot Study of the Effect of h5G1.1-mAb on Dermatomyositis Patients |
| Lead sponsor | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Dermatomyositis |
| Intervention type | Drug |
| Interventions | h5G1.1-mAb |
| Enrollment | 17 |
| Start date | Apr 1, 2000 |
| Completion | Dec 1, 2001 |
| First posted | Apr 26, 2000 |
| Last update posted | Mar 4, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: